


CLAIM AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-15 (cancelled)

Claim 16 (currently amended): A method of providing a pharmacological agent to an eye for ophthalmologic use, that causes little or no damage to the retina, even when used long term, treating an eye comprising the step of applying at least one highly fluorinated oligomeric compound of the general formula



wherein

R_F is a linear or branched perfluorinated alkyl chain C_2F_5 to $\text{C}_{12}\text{F}_{25}$,

R^1 and R_2 are independently selected from the group H, CH_3 , C_2H_5 and C_3H_7 ,

n is selected from the integers 0, 1 and 2, and

x is an integer from 2 to 6,

having a molecular weight of at least 750

to an eye as an ophthalmologic pharmacological treating agent.

Claim 17 (previously presented): The method of claim 16 wherein the application to the eye is as one of a vitreous body substitute and a retina tamponade.

Claim 18 (previously presented): The method of claim 16 wherein the application to the eye is as a liquid implant.

Claim 19 (previously presented): The method of claim 16 wherein the application to the eye is as a tear substitute.

Claim 20 (previously presented): The method of claim 16 wherein pharmacological agents are mixed with the highly fluorinated oligomeric compound which acts as a carrier therefore before applying to the eye.

Claim 21 (previously presented): The method of claim 16 wherein a plurality of different ones of said highly fluorinated oligomeric compounds are mixed together before applying to the eye.

Claim 22 (previously presented): The method of claim 16 wherein said highly fluorinated oligomeric compound is a component of a pharmacological preparation that is applied to the eye.